Dolastatin analogue - Chugai/Roche

Drug Profile

Dolastatin analogue - Chugai/Roche

Alternative Names: Dolastatin analogue (Compound 1) - Chugai/Roche; Dolastatin analogue - Chugai/Hoffmann-La Roche

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Chugai Pharmaceutical; Roche
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Japan
  • 14 May 2007 Chugai and Roche have completed enrolment in their phase I trial for Cancer
  • 12 May 2005 Phase I trials in Solid tumours in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top